and Mike. thank us. you joining Good everyone, afternoon, for Thanks,
QX obvious Let essentially which XXX,XXX into processed get patients cancer process you for the believe our will separate in I'm quarter, $XX.X screening. another areas. transplant impacts strong highlights. enrolling reimbursed in gross trial in the tests with for product Prospera. of grew revenues BESPOKE me that the are We rejection These saw these on COVID-XX. was large Natera. now and to kidney colorectal was proactive XX% QX from We revenues and have in in extend three the margin very leadership year-on-year volumes, and in despite a sure all-time Signatera IDEA-CIRCULATE record generated par prospective we approximately started trials get quarter our We for trials, many XX% key completed Prospera on for the that we position million
values. leaders Force recognized Natera’s paid very expected an individual Women of contributions is Clinical We women leads is over receive over from by Natera, Cochair we Education Parmar, to employee past Natera an equality Services at companies that for Women day. Sheetal teams pleased supports who Illuminator as workplace which and mission recognized being group resource far, was her in of and so organization in CMS. XXX also and Entrepreneurs, Medical and diversity the the the Award is innovative outstanding And are were Change Leading of that
women of their the say to wanted effort, leadership. in just monitoring. our oncology In we So Natera you first Sheetal for and thank congratulate IO and
demonstrating ability tumor the Cancer, Just in study saw XX Nature groundbreaking this publication monitor we cancer. of a response to of different to types validation Signatera's solid week, immunotherapy in
presented that for metastatic very cancer, at follow. supports ASCO we strong Second a of data, on publication in clinic Signatera use GI ESMO and new expansion the with prospective announce to Based the data colorectal nearly colorectal today Signatera, pleased to we're opportunities I'm together represent where new see cancer, for colorectal tests opportunities these three slide. per on previous this XXX,XXX can market two We and addressable associated seeking cancer. with reimbursement year, as think additional doubling you our approximately stage two next
for Medicare be decision local colorectal would indication to second reimburse expand indication our clinical In clinical to path pre-submission submit a major for dossier and meeting for our combined, indication cancer, clear in we represent IO plan completed In and we cancer monitoring, all we this the previous roughly tests per coverage already what positive commercialization colorectal reimbursement submitted soon. that metastatic we formally year. and Signatera. think settings a So have have million X to
we've about describe the we Each last up XXXX by from in The in very the we've the Solomon the pullback large XXXX, volume QX. typically the QX years. in these volumes detail of And volumes past, described years factors seasonal is QX In pulled the record smaller more shows quarter. of to later remarkable, our half just point QX X% performance few below to will in in a QX. XXXX. QX saw call. in are our step then of due slide disruption the versus a over indications This This given a XXXX. economy percentage scale prior QX next year seen back volumes that
out to of the order figured QX call. good weeks their a weekly - in of of of later recover outbreak, onset year. levels, feeling weeks as customers saw the XX% existing services, we're early ability in volume also the to and last grow, in our testing. more the to few need new win won customers saw COVID-XX toward we surges in accounts. then to to two April. existing our practices our half volumes accounts the drop But about we QX and starts the immediately weekly reopen March COVID-XX first the the And received we to During of prenatal we second In about maintain will about non-invasive a outlook like new weather talk critical how Mike in
we good unfettered think to While tools. a since new and has win clearly I still of remote it's clinic, rep a we wins to easier number encouraging our have use earnings business of And a have call. when customer built access last our made
to you'd revenue about I’d trajectory the shows QX for the from XXXX, partner of note next revenue a over Medicine but expect, The only recognition monitoring in XXXX. slide included we're the and optimistic that BGI cautiously situation million time. BGI we're QX combined half about of as million $X.X Foundation So year. in of $X compared second
in strong, had next product as The intact. I the typical underlying is trends momentum our expected, which think business mentioned. the shows and view, revenue remain ASP our as slide COGS in I we is and very So came
front, the had the On headwinds quarter. we ASP both and in tailwind
core have health much test we as per As was price more expected, our sell centers elective, reproductive channel a core The it many considered IVF IVF in initially products severely channel, channel impacted than the than that higher closed. channel. and much was average our
a we suffered So product from favorable bit mix. a less
the IVF issue. likely quarters, we we of our just had that can next weekend main in due customers volume The a way will happens. in their to forward timing were favour four push a risk glad end that in the coverage I was see. to tailwind of these they've more lot now on of over that which saw that's three to the the swing It's very average we IVF a hold were put the to coverage NIPT when pandemic. Aetna, find year, spring to course think the so think that the And chosen extending of extend to I
completed, expect as I average less we of potential be status roughly this or presented adoption now is ASP around and conference ASP to the outlined. is The risk study study. and factors six result quo, as So the in to given long and enrollment term data the One expected both view SMFM other publication benefit the published months. SMART more
XX,XXX is for the landmark five a patient we've reminder, years. clinical been prospective past site running SMART trial multi As a
multiple The aneuploidy microdeletions. one average focused both study, and to in fetal focus the the analyzed has one released. from risk expect aneuploidy been on on and data and be papers high has We risk yet data pregnancies, microdeletion
microdeletion this to trial society Although the for coverage impact we guidelines we think and have a on be the average can't risk positive performance, completed, both indications. SMART comment aneuploidy perspective, could largest policies on because and is
same to redundancy step COVID-XX, further trial last next in and at improvement takeaway workflow validation maintain robust with the operations than demand said for coming Panorama given completed. our quarter. out improvements to to they got leadership including COGS anticipate over our quarters. largely expansion Austin lab lab that I've the added change the make the expect we that in some R&D QX. additional caused the needing few unit also data per that, we in year fortify SMART QX new did sure We redundancy the extends that in to We better Having have facility, generate a for performed versus clinical team even to are our
the reproductive achievable. plan very is we're $XXX our So below confident for for COGS health business
as note,, for product health change business $XXX changes well. our new Now like to last the point as products mix average below Signatera, important to getting include it's COGS will the reproductive
we'll some the future COGS. health I but these overall on in color metrics, reproductive So separate track giving anticipate
us reproductive to lower. from achieve growth, the the cash walked and the goal one business. COGS the that This scale number ASPs goal, track to the COVID-XX, while Despite the strategic that we've we just of to recall, will from we business company variables getting that all flow rapidly health stable get is You through breakeven. in all impacts volume comes confidence the are on new give
lab California safety offers redundancy efficiencies We've our Austin than this for and additional a consistent model both of was lab protocols of executed X for wide confident feel new tests once operations these in more critical scaling smoothly Austin mentioned launched for a our slide to second and need as critical also and be available to patients The and for starting and well. be to have This know mobile Prospera, monitored. seen you new Signatera this the accounts expansion tools protective which check-in The despite critical cost the I offering of testing pandemic. given million future more a be environment. and have capacity tend We've scale. proved one to in for compromised also it consistently we been patients good sold are and goods array at and should operational lab COVID. have labs us gives particularly customers offer mobile to annually years response on the nicely. Just
focus Okay, now, the business. let me shift the to Transplant
I to we're slide mentioned, it. get very reimbursement slide we're to Prospera. final now we first for presented retire XXXX. pleased happy As This same the is And in
we As program. later course consistent Medicare you'll received submit pricing the Prospera for in a now claims call, assigned with and able per see so indications the for of of to been same oncology. and to We've the of us test final by number to MolDx following reimbursement XXXX path far the
can now we centers. transplant described for commercial Prospera ongoing demonstrated be pandemic, broad could of executed which have contributor confident early our the phase for of that our the on pre during we continue company. had to call feel So success in despite last launch. the a Prospera, the We the the significant launch. a swath we in launch access And we that our days We're still we
the test. of the the data on improve slide, we've and generate to described next As performance continued
DNA refine built we have that provide This patients tests of with an that improvement commercially run that data levels elevated can at huge information. can Prospera's Given the million algorithm. spring, set background up Natera, algorithm we more in to to further we critical cell-free This DNA cell-free than we blood. query a their launched identifies X
who risk For example, to donor background of levels of might extremely is us result, COVID-XX patients be identify can negative simply to elevated allows false able cell-free of the we've seen patients an where background elevated DNA. levels at Being have DNA elevated diluted very background signal. by affected signal by a identify
to plan transplant excited technology most continuing help two at new announced largest So leadership leverage year. that patients and Brennan to second in study this across Bunnapradist trial, validate PEDAL XXX DNA and our early centers prestigious physician we enhanced And and world. study success Hopkins and study prospective Dr. from two Dr. look launch our and externally we ATC a major the the the perception. ATC transplant These we of in also from And run algorithm. the forward to we year. presented of this on to great this to several patients several the in to case studies the Johns cell-free UCLA introduced are at We're researchers expertise premier our of half the from centers. scientific
reins oncology. in to me over to our Solomon hand the let Now, progress cover
Solomon?
